Reimagining Gene and Cell Therapy: Helen Sabzevari on Precigen's Breakthroughs in Precision Medicine

In this episode of BioTalk, Rich Bendis welcomes Dr. Helen Sabzevari, President and CEO of Precigen, to discuss the company's cutting-edge science in gene and cell therapy. Dr. Sabzevari shares how Precigen's unique AdenoVerse® platform has powered the development of PRGN-2012, a potential first-in-class therapeutic currently under FDA priority review for the treatment of adults with recurrent respiratory papillomatosis (RRP), a rare and devastating disease. She also highlights advances across Precigen's broader pipeline in immuno-oncology and autoimmune disease and reflects on how Maryland's BioHealth Capital Region has supported the company's innovation and growth. Editing and post-production work for this episode was provided by The Podcast Consultant. Dr. Helen Sabzevari is the President and CEO of Precigen, Inc. , and a leading expert in immunotherapy-based therapeutics. She previously served in executive roles at Compass Therapeutics and Merck KGaA/EMD Serono, where she advanced numerous immuno-oncology programs. Dr. Sabzevari began her career at the National Cancer Institute and has been widely recognized for her leadership and scientific contributions, including honors from NIH, SITC, and Forbes.

You can listen to Reimagining Gene and Cell Therapy: Helen Sabzevari on Precigen's Breakthroughs in Precision Medicine online on Radio and Podcast. Open the player on this page to stream the available audio.

Reimagining Gene and Cell Therapy: Helen Sabzevari on Precigen's Breakthroughs in Precision Medicine is an episode from BioTalk with Rich Bendis by BioHealth Innovation, Inc. (BHI).

This episode is 38:25 long.

This episode was published on Jul 6, 2025.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from BioTalk with Rich Bendis when more episodes are available from the podcast feed.